AQS — Aequus Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- CA$0.66m
- CA$7.23m
- CA$0.58m
Annual income statement for Aequus Pharmaceuticals, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2.59 | 2.71 | 1.38 | 0.255 | 0.584 |
| Cost of Revenue | |||||
| Gross Profit | — | 2.69 | 1.28 | 0.144 | 0.332 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 3.64 | 4.54 | 4.66 | 3.22 | 2.96 |
| Operating Profit | -1.05 | -1.82 | -3.28 | -2.97 | -2.38 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.05 | -1.81 | -3.21 | -2.96 | -2.18 |
| Net Income After Taxes | -1.05 | -1.81 | -3.21 | -2.96 | -2.18 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.05 | -1.81 | -3.21 | -2.96 | -2.18 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.05 | -1.81 | -3.21 | -2.96 | -2.18 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.011 | -0.014 | -0.02 | -0.022 | -0.016 |